On September 25, 2020, California Governor Gavin Newsom signed into law AB 713, amending the California Consumer Privacy Act (CCPA). Importantly, the bill clarifies the standard by which patient information is deemed de-identified and therefore exempt from CCPA. It also expands the law’s research exception beyond research associated with clinical trials. Both changes are welcome clarifications for the healthcare, research and life sciences communities. The bill also contains new notice and contract obligations related to the sale or license of de-identified patient information, which are likely to have widespread implications.
The bill was passed as an urgency statute that takes effect immediately, with the California legislature recognizing that “[t]he provisions of [AB 713] would mitigate [the] harm [posed by the CCPA] as soon as possible by preserving access to information needed to conduct important health-related research that will benefit Californians.” This article analyzes the bill as finalized.
Elimination of De-identification Ambiguity and Expansion of Research Exceptions
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
